ChromaDex Corporation (CDXC) financial statements (2022 and earlier)
Company profile
| Business Address |
10900 WILSHIRE BLVD LOS ANGELES, CA 90024 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 17 | 19 | 23 | 45 | 2 | 6 | 4 | ||
| Cash and cash equivalents | 17 | 19 | 23 | 45 | 2 | 6 | 4 | ||
| Receivables | (1) | 2 | 5 | 5 | 6 | 2 | 2 | ||
| Inventory, net of allowances, customer advances and progress billings | 12 | 12 | 8 | 6 | 8 | 8 | 4 | ||
| Inventory | 12 | 12 | 8 | 6 | 8 | 8 | 4 | ||
| Other undisclosed current assets | 5 | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Total current assets: | 32 | 34 | 37 | 57 | 16 | 17 | 10 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 3 | 4 | 4 | 3 | 3 | 2 | 1 | ||
| Long-term investments and receivables | 0 | ||||||||
| Long-term investments | 0 | ||||||||
| Intangible assets, net (including goodwill) | 1 | 1 | 2 | 2 | 0 | 0 | 0 | ||
| Intangible assets, net (excluding goodwill) | 1 | 1 | 2 | 2 | 0 | 0 | 0 | ||
| Regulated entity, other noncurrent assets | 0 | 0 | |||||||
| Deposits noncurrent assets | 0 | 0 | 0 | 0 | 0 | ||||
| Other noncurrent assets | 1 | 1 | 0 | 0 | |||||
| Other undisclosed noncurrent assets | 1 | (1) | |||||||
| Total noncurrent assets: | 6 | 7 | 6 | 6 | 4 | 2 | 2 | ||
| TOTAL ASSETS: | 38 | 40 | 42 | 63 | 20 | 19 | 12 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 16 | 14 | 14 | 7 | 8 | 8 | 4 | ||
| Accounts payable | 9 | 10 | 10 | 4 | 6 | 6 | 3 | ||
| Accrued liabilities | 6 | 4 | 4 | 4 | 2 | 1 | 1 | ||
| Employee-related liabilities | 0 | ||||||||
| Interest and dividends payable | 0 | 0 | |||||||
| Debt | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Due to related parties | 0 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current liabilities | 0 | 0 | 0 | 0 | 0 | 2 | 0 | ||
| Total current liabilities: | 16 | 15 | 14 | 8 | 9 | 10 | 5 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | 1 | 0 | 0 | 0 | 4 | 2 | ||
| Long-term debt, excluding current maturities | 3 | 2 | |||||||
| Finance lease, liability | 0 | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Capital lease obligations | ✕ | ✕ | 0 | 0 | 0 | 0 | 0 | ||
| Operating lease, liability | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 4 | 4 | 0 | 0 | 0 | (0) | (0) | ||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 0 | (0) | (0) | ||
| Deferred revenue | 4 | 4 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | 0 | 0 | 0 | 0 | 0 | ||||
| Total noncurrent liabilities: | 5 | 5 | 1 | 1 | 1 | 4 | 3 | ||
| Total liabilities: | 22 | 20 | 15 | 9 | 10 | 13 | 8 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 16 | 20 | 27 | 54 | 10 | 5 | 4 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 158 | 142 | 117 | 110 | 55 | 47 | 43 | ||
| Accumulated deficit | (142) | (122) | (90) | (57) | (45) | (42) | (40) | ||
| Other undisclosed stockholders' equity attributable to parent | (0) | 0 | |||||||
| Total stockholders' equity: | 16 | 20 | 27 | 54 | 10 | 5 | 4 | ||
| TOTAL LIABILITIES AND EQUITY: | 38 | 40 | 42 | 63 | 20 | 19 | 12 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 59 | 46 | 32 | 21 | 27 | 22 | 15 | |
| Revenue, net | ✕ | ✕ | 3 | 21 | 27 | 22 | 15 | |
| Revenue from related parties | 9 | 7 | ✕ | ✕ | ✕ | ✕ | ||
| Cost of revenue | (24) | (21) | (16) | (11) | (15) | (14) | (10) | |
| Gross profit: | 35 | 26 | 16 | 10 | 12 | 8 | 5 | |
| Operating expenses | (55) | (57) | (49) | (27) | (14) | (11) | (11) | |
| Operating loss: | (20) | (31) | (33) | (16) | (2) | (2) | (5) | |
| Nonoperating expense | (0) | (1) | (0) | (0) | (1) | (1) | (0) | |
| Investment income, nonoperating | 5 | 0 | 0 | 0 | ||||
| Interest and debt expense | (0) | (1) | (0) | (0) | (0) | (1) | (0) | |
| Loss from continuing operations before equity method investments, income taxes: | (20) | (33) | (33) | (17) | (3) | (3) | (6) | |
| Other undisclosed income from continuing operations before income taxes | 0 | 0 | 1 | |||||
| Loss from continuing operations before income taxes: | (20) | (33) | (33) | (17) | (3) | (3) | (6) | |
| Income tax expense | (0) | |||||||
| Loss from continuing operations: | (20) | (33) | (33) | (17) | (3) | (3) | (6) | |
| Income from discontinued operations | 5 | |||||||
| Net loss: | (20) | (33) | (33) | (11) | (3) | (3) | (6) | |
| Other undisclosed net income attributable to parent | 0 | 1 | 0 | 0 | ||||
| Net loss available to common stockholders, basic: | (20) | (32) | (33) | (11) | (3) | (3) | (5) | |
| Dilutive securities, effect on basic earnings per share | 12 | |||||||
| Net loss available to common stockholders, diluted: | (8) | (32) | (33) | (11) | (3) | (3) | (5) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (20) | (33) | (33) | (11) | (3) | (3) | (6) | |
| Comprehensive loss, net of tax, attributable to parent: | (20) | (33) | (33) | (11) | (3) | (3) | (6) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.